A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT06952426
Status
Recruiting
Apply to this trial

Conditions

  • Immunoglobulin A Nephropathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • No intervention — OTHER
    Participants and their caregivers will report home reported outcomes (HRO) data on symptom burden to understand symptom variability and health-related quality of life (HRQoL).
  • Other treatment — OTHER
    Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL.
  • Iptacopan — OTHER
    Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking iptacopan.
  • Atrasentan — OTHER
    Participants and their caregivers will report HRO data on symptom burden and treatment usage to understand symptom variability and HRQoL including those taking atrasentan.

Study Details

The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.

Key Dates

Start date
Mar 4, 2025
Status verified
Jun 2025
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Immunoglobulin A nephropathy (IgAN)-Iptacopan
    IgAN patients taking iptacopan and their caregivers
  • Arm: IgAN-atrasentan
    IgAN patients taking atrasentan and their caregivers
  • Arm: IgAN-other treatment
    IgAN patients taking other specific treatment and their caregivers
  • Arm: IgAN-no treatment
    IgAN patients taking none treatment and their caregivers

Primary Outcome Measure

Number of participants with IgAN specific symptoms [ Time Frame: monthly up to month 6 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Novartis Investigational siteBostonMassachusetts02108-

Find similar trials in Boston, MA

By research site
Novartis Investigational site· Boston, MA

Related Studies